Korde, Neha
Mayo Clinic
Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Citations 2
Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry
Maclachlan, Kylee , Papadimitriou, Marios , Blaney, Patrick , Baughn, Linda B. , Shekarkhand, Tala , Poos, Alexandra M. , Ziccheddu, Bachisio , Tang, Hongwei , Yan, Huihuang , Diamond, Benjamin , Zhang, Yanming , Cimera, Robert , Hultcrantz, Malin , Mailankody, Sham , Hassoun, Hani , Tan, Carlyn , Brown, Elizabeth , Winterkorn, Lara , Steinsnyder, Zoe , Vaksman, Zalman , Korde, Neha , Weinhold, Niels , Maclachlan, Kylee , Tang, Hongwei , Dogan, Ahmet , Gagler, Dylan , Boyle, Eileen M , Hultcrantz, Malin , Mailankody, Sham , Hassoun, Hani , Shah, Urvi A , Tan, Carlyn R , Brown, Elizabeth E , Winterkorn, Lara , Chu, Timothy , Steinsnyder, Zoe , Vaksman, Zalman , Davies, Faith E , Korde, Neha , Landgren, C Ola , Raab, Marc S , Lesokhin, Alexander M , Robine, Nicolas , Weinhold, Niels , Usmani, Saad , Maura, Francesco , Morgan, Gareth J , Baughn, Linda B , Diamond, Benjamin T , Blaney, Patrick , Poos, Alexandra M. , Doǧan, Ahmet , Boyle, Eileen M. , Shah, Urvi A. , Davies, Faith E. , Landgren, Ola , Raab, Marc S. , Lesokhin, Alexander M. , Usmani, Saad Z. , Maura, Francesco , Morgan, Gareth J.
Blood Cancer Discovery | June 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF17
Abstract Studies have reported conflicting findings regarding the contribution of germline variants or somatic genomic drivers to racial disparities in multiple myeloma. To comprehensively investigate somatic drivers in relation to inherited genetics in multiple myeloma, we combined newly sequenced whole-genome sequencing data with publicly available datasets (total n = 1,286). Overall, we did not identify germline or somatic genomic differences that explain the different risk of developing multiple myeloma between patients with genetic similarity to African (AFR) or European (EUR) reference populations. A difference in the detectability and timing of APOBEC-associated and germinal center mutational activity was observed. Integrating epidemiologic data and mutational signature-based temporal estimates, we challenge the assumption that individuals in the AFR group develop multiple myeloma at a younger age. Finally, we demonstrate that, with equal access to efficacious therapies, patients in the AFR and EUR groups have equivalent clinical outcomes. Significance: Multiple myeloma is reported to occur at higher rates in individuals who self-identify as non-Hispanic Black. In this large dataset, genomic drivers occur at the same rate among ancestry groups, except for APOBEC mutagenesis. With equivalent therapy, clinical outcomes did not differ for patients grouped by genetic ancestry similarity.
A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model
Shah, Urvi A. , Cogrossi, Laura Lucia , Garcés, Juan‐José , Policastro, Anna , Castro, Francesca , Derkach, Andriy , Fei, Teng , DeWolf, Susan , Grioni, Matteo , Sisti, Sofia , Blaslov, Jenna , Adintori, Peter , McAvoy, Devin , Baichoo, Mirae , Paredes, Jenny , Anuraj, Aishwarya , Pohl, Charlotte , Zinsmeyer, Victoria , Gipson, Brianna , Marchigiani, Camilla , Pagani, Sara , Salehi, Erica , Block, Torin , Korde, Neha , Tan, Carlyn , Hultcrantz, Malin , Hassoun, Hani , Scordo, Michael , Lahoud, Oscar , Landau, Heather , Peled, Jonathan U. , Chesi, Marta , Mailankody, Sham , D’Souza, Anita , Iyengar, Neil M. , Adintori, Peter A , Hosszu, Kinga K , McAvoy, Devin , Baichoo, Mirae , Cross, Justin R , Paredes, Jenny , Anuraj, Aishwarya , Raj, Sandeep S , Pohl, Charlotte , Zordan, Paola , Zinsmeyer, Victoria , Jesus Faustino Ramos, Ruben J , Lorenzoni, Marco , Gipson, Brianna , Maclachlan, Kylee , Gradissimo, Ana , Boiocchi, Leonardo , Aleynick, Nathan , Marchigiani, Camilla , Pagani, Sara , Salehi, Erica , Koche, Richard P , Chaligne, Ronan , Block, Torin , Korde, Neha , Tan, Carlyn R , Hultcrantz, Malin , Hassoun, Hani , Shah, Gunjan L , Scordo, Michael , Lahoud, Oscar B , Chung, David J , Landau, Heather , Peled, Jonathan U , Clementi, Nicola , Chesi, Marta , Bergsagel, P. Leif , Mailankody, Sham , Pollak, Michael N , D'Souza, Anita , Landgren, C Ola , Chimonas, Susan , Giralt, Sergio , Usmani, Saad , Iyengar, Neil M , Lesokhin, Alexander M , van den Brink, Marcel R M , Bellone, Matteo , Shah, Urvi A , Derkach, Andriy , Garces, Juan-Jose , Fei, Teng , Maclachlan, Kylee , Aleynick, Nathan , Shah, Gunjan L. , Bergsagel, P. Leif , Pollak, Michaël , Landgren, Ola , Giralt, Sergio , Usmani, Saad Z. , Lesokhin, Alexander M. , Bellone, Matteo
Cancer Discovery | December 4, 2025 | Volume: 16 | Issue: 4 | Pages: 697-720
Abstract Consumption of a Western diet and high body mass index (BMI) are risk factors for progression from premalignant phenotypes to multiple myeloma, a hematologic cancer. In the NUTRIVENTION trial (NCT04920084), we administered a high-fiber, plant-based diet (HFPBD; meals for 12 weeks, coaching for 24 weeks) to 23 participants with myeloma precursor states and elevated BMI. The intervention was feasible and improved quality of life and modifiable risk factors: metabolic (BMI, insulin resistance), microbiome (diversity, composition), and immune (inflammation, monocyte subsets). Disease progression trajectory improved (n = 2) or was stable. Findings were translated to Vk*MYC mice modeling the myeloma precursor state, in which a high-fiber diet (HFD) delayed disease progression through improved metabolism and microbiome composition, leading to increased short-chain fatty acid production that reinvigorated antitumor immunity and inhibited tumor growth. These effects from fiber consumption were independent of calorie restriction and weight loss. A HFD is a low-risk intervention that may delay progression to myeloma. Significance: A HFPBD in participants with precursor plasma cell disorders and an elevated BMI improved metabolic, microbiome, and immune biomarkers of disease. In a subset, it may delay progression to myeloma. In mouse models, a HFD delayed progression to myeloma independent of calorie restriction. See related commentary by Fairfield and Reagan, p. 623